Norris Medicines Ltd has scheduled its 35th Annual General Meeting for September 29, 2026. Key agenda items include the appointment of Vimal D. Shah as MD and authorizations for borrowing and asset disposal up to Rs 50 crore. Despite a rise in annual revenue, the company continues to report net losses, negative working capital, and significant auditor qualifications regarding gratuity liabilities and regulatory compliance.
Norris Medicines AGM Agenda: Borrowing and Asset Disposal Proposals
Revenue rose to Rs 8.13 crore in FY26; Net loss narrowed to Rs 0.28 crore.
Reader Takeaway: Shareholders face critical decisions on liquidity-focused resolutions amid persistent negative working capital and auditor-flagged compliance issues.
What just happened
Norris Medicines Ltd has announced its 35th Annual General Meeting (AGM) to be conducted via video conferencing on September 29, 2026. The board has placed several high-stakes special resolutions before shareholders, primarily focused on enhancing the company's financial flexibility. These include appointing Vimal D. Shah as Managing Director for a three-year term with a remuneration cap of Rs 24 lakh per annum, and seeking authorization to borrow funds and dispose of assets up to a limit of Rs 50 crore.
Why this matters
The proposed Rs 50 crore borrowing and asset disposal limits highlight the company's current liquidity stress. As of March 31, 2026, the firm reported a negative working capital of Rs 3.71 crore. These resolutions are aimed at securing operational liquidity, though they grant the management significant authority over the company's asset base.
The backstory
The company remains in a loss-making phase, though FY26 saw a reduction in the net loss to Rs 0.28 crore compared to the Rs 1.24 crore loss in FY25. Operating revenue saw a modest increase to Rs 8.13 crore from Rs 5.82 crore in the previous year. However, the company faces ongoing pressure from pending annual listing fees for FY 2026-27 and historical arrears.
Risks to watch
Auditors have issued a qualified opinion, citing two major concerns: the lack of actuarial provision for gratuity liabilities and non-compliance with the Payment of Gratuity Act. Additionally, the company’s accounting software currently lacks the mandated audit trail feature required by law. Investors should also note a BSE-imposed penalty of Rs 24,780 for the delayed filing of investor complaints in 2025.
What to track next
The outcome of the voting on special resolutions will determine the company's ability to raise capital. Furthermore, the company's timeline for rectifying its accounting software audit trail and settling its outstanding statutory and listing fee obligations will be key indicators of improving governance.